Search papers, labs, and topics across Lattice.
This study introduces AURA, a novel method for accurately identifying the active antibiotics in bacterial samples, addressing the challenge posed by treatment ambiguity where resistant drugs leave no morphological trace. The research reveals that traditional methods incorrectly assume the applied antibiotics equate to the active ones only 37% of the time, highlighting a significant gap in existing computational tools. AURA employs a constrained, energy-based inverse attribution approach to effectively infer the active subset of antibiotics, achieving an impressive 95.47% exact-match accuracy in cross-replicate testing on E. coli samples.
AURA achieves 95.47% accuracy in identifying active antibiotics, revealing that traditional methods misidentify the active set over 60% of the time.
When a bacterial sample is exposed to several antibiotics, not every applied drug necessarily acts: if the organism is resistant to one of them, that drug leaves no morphological trace. The clinically meaningful quantity is therefore not which antibiotics were applied, but which ones were active. We show that these two are sharply decoupled in real E. coli microscopy - naively assuming the applied combination equals the active one is correct only about 37% of the time - yet existing computational tools are ill-suited to recovering the active set. Forward perturbation models such as scGen, CPA, and IMPA are designed to predict appearance from treatment, not the reverse, and inverting them degrades sharply; discriminative image classifiers tend to memorise strain- and batch-specific texture and fail to transfer across experimental replicates. We introduce AURA, which reframes the task as constrained, energy-based inverse attribution. Its central inductive bias is that the active set must be a subset of the applied set; this collapses the candidate space and lets AURA infer the active subset of applied antibiotics by decomposing residual morphology into antibiotic response atoms and selecting the subset with the lowest reconstruction energy, using no strain label at test time. AURA-E adds evidence-aware abstention, withholding a prediction when candidate explanations remain near-equally plausible. On cross-replicate transfer in an E. coli cytological profiling dataset, AURA recovers the active antibiotic combination with 95.47% exact-match accuracy.
NUS